Trial Profile

A trial assesssing Erlotinib gel (SGT-210) in patients with punctate palmoplantar keratoderma type -1 (PPPK type 1)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Jul 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Erlotinib (Primary)
Indications Palmoplantar keratoderma
Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use
Sponsors Sol-Gel Technologies

Most Recent Events

28 Jun 2021 Status changed from recruiting to completed.
04 Mar 2021 According to a Sol-Gel Technologies, The enrollment of patients in the Phase 1 proof-of-concept study with SGT-210 (erlotinib gel) in patients with palmoplantar keratoderma has been slowed by the COVID-19 pandemic. The Company expects to report top-line data in the third quarter of 2021.
12 Nov 2020 According to a Sol-Gel Technologies media release, the company expects the top-line results from this study by year-end 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com